Assessment of Five-Year Relative Survival of Patients With Endometrial Cancer: A Period Analysis.

IF 2.1 Q3 ONCOLOGY World Journal of Oncology Pub Date : 2024-10-01 Epub Date: 2024-08-10 DOI:10.14740/wjon1921
Xiao Jiao Zhao, Xin Bing, Qi Qi Lei, Yong Ran Cheng, Jun Yang, Liang You Wang, Tian Hua Chen, Tian Hui Chen
{"title":"Assessment of Five-Year Relative Survival of Patients With Endometrial Cancer: A Period Analysis.","authors":"Xiao Jiao Zhao, Xin Bing, Qi Qi Lei, Yong Ran Cheng, Jun Yang, Liang You Wang, Tian Hua Chen, Tian Hui Chen","doi":"10.14740/wjon1921","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Endometrial cancer is one of the most common female cancers globally and in China. Although timely assessment of 5-year relative survival is crucial for guiding secondary prevention and early screening programs for endometrial cancer patients, those kinds of data are scarce in China. We aimed to provide a timely and accurate assessment of 5-year relative survival for patients with endometrial cancer from eastern China.</p><p><strong>Methods: </strong>Overall, 945 patients diagnosed with endometrial cancer during 2004 - 2018 from four cancer registries with high-quality data from Taizhou, eastern China were included. Period analysis was used to calculate 5-year relative survival for overall and the stratification by age at diagnosis and region. Model-based period analysis was used to predict the 5-year relative survival for the upcoming period of 2019 - 2023.</p><p><strong>Results: </strong>We found that 5-year relative survival during 2014 - 2018 reached 86.4% for overall, while urban areas had higher survival compared to rural areas (91.3% vs. 85.3%). Furthermore, there was a clear age gradient, decreasing from 89.3% for age < 55 years to 80.5% for age > 74 years. Predicted 5-year relative survival for the upcoming period 2019 - 2023 could reach 88.4%.</p><p><strong>Conclusions: </strong>We provide, a timely and accurate assessment of 5-year relative survival for patients with endometrial cancer from Taizhou, eastern China, reaching 86.4% for overall. Our finding has important implications for the overall evaluation of early detection and screening programs for patients with endometrial cancer in eastern China.</p>","PeriodicalId":46797,"journal":{"name":"World Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":2.1000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11424110/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.14740/wjon1921","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/10 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Endometrial cancer is one of the most common female cancers globally and in China. Although timely assessment of 5-year relative survival is crucial for guiding secondary prevention and early screening programs for endometrial cancer patients, those kinds of data are scarce in China. We aimed to provide a timely and accurate assessment of 5-year relative survival for patients with endometrial cancer from eastern China.

Methods: Overall, 945 patients diagnosed with endometrial cancer during 2004 - 2018 from four cancer registries with high-quality data from Taizhou, eastern China were included. Period analysis was used to calculate 5-year relative survival for overall and the stratification by age at diagnosis and region. Model-based period analysis was used to predict the 5-year relative survival for the upcoming period of 2019 - 2023.

Results: We found that 5-year relative survival during 2014 - 2018 reached 86.4% for overall, while urban areas had higher survival compared to rural areas (91.3% vs. 85.3%). Furthermore, there was a clear age gradient, decreasing from 89.3% for age < 55 years to 80.5% for age > 74 years. Predicted 5-year relative survival for the upcoming period 2019 - 2023 could reach 88.4%.

Conclusions: We provide, a timely and accurate assessment of 5-year relative survival for patients with endometrial cancer from Taizhou, eastern China, reaching 86.4% for overall. Our finding has important implications for the overall evaluation of early detection and screening programs for patients with endometrial cancer in eastern China.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
子宫内膜癌患者五年相对生存率评估:周期分析
背景:子宫内膜癌是全球和中国最常见的女性癌症之一:子宫内膜癌是全球和中国最常见的女性癌症之一。虽然及时评估 5 年相对生存率对于指导子宫内膜癌患者的二级预防和早期筛查计划至关重要,但此类数据在中国却很少。我们的目标是及时准确地评估华东地区子宫内膜癌患者的 5 年相对生存率:方法:纳入2004-2018年期间从中国东部台州地区4个具有高质量数据的癌症登记处确诊的945名子宫内膜癌患者。采用周期分析法计算总体5年相对生存率,并根据诊断年龄和地区进行分层。基于模型的周期分析用于预测2019-2023年的5年相对生存率:我们发现,2014-2018年期间,总体5年相对生存率达到86.4%,而城市地区的生存率高于农村地区(91.3%对85.3%)。此外,存在明显的年龄梯度,从年龄小于55岁的89.3%降至年龄大于74岁的80.5%。预测2019-2023年的5年相对存活率可达88.4%:我们及时准确地评估了中国东部台州地区子宫内膜癌患者的 5 年相对生存率,总体达到 86.4%。我们的研究结果对于全面评估华东地区子宫内膜癌患者的早期发现和筛查项目具有重要意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.10
自引率
15.40%
发文量
37
期刊介绍: World Journal of Oncology, bimonthly, publishes original contributions describing basic research and clinical investigation of cancer, on the cellular, molecular, prevention, diagnosis, therapy and prognosis aspects. The submissions can be basic research or clinical investigation oriented. This journal welcomes those submissions focused on the clinical trials of new treatment modalities for cancer, and those submissions focused on molecular or cellular research of the oncology pathogenesis. Case reports submitted for consideration of publication should explore either a novel genomic event/description or a new safety signal from an oncolytic agent. The areas of interested manuscripts are these disciplines: tumor immunology and immunotherapy; cancer molecular pharmacology and chemotherapy; drug sensitivity and resistance; cancer epidemiology; clinical trials; cancer pathology; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; gene therapy; cancer endocrinology; cancer metastasis; prevention and diagnosis of cancer; other cancer related subjects. The types of manuscripts accepted are original article, review, editorial, short communication, case report, letter to the editor, book review.
期刊最新文献
Analysis of Pancreatic Cancer Genetic Risk Factors in a Multi-Ethnic Population Sample. Assessment of Five-Year Relative Survival of Patients With Endometrial Cancer: A Period Analysis. Correction to: Empowerment-Led Guided Self-Help Intervention for Symptom Burden in Breast Cancer Women Treated With Ovarian Function Suppression: A Randomized Trial Protocol. Cryotherapy in the Treatment of Early-Stage Breast Cancer. Multi-Gene Panel Testing for Hereditary Cancer Predisposition Among Patients Sixty-Five Years and Above Diagnosed With Breast Cancer.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1